Crispr Therapeutics upgraded to Hold from Sell at TD Cowen
TD Cowen upgraded Crispr Therapeutics (CRSP) to Hold from Sell with an unchanged price target of $35. The firm continues to be cautious on the ...
Crispr Therapeutics price target raised to $120 from $100 at Truist
Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...
CRISPR upgraded to hold by TD Cowen on limited downside
TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...
CRISPR Therapeutics posts narrower-than-feared loss, beats revenue estimates
ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.
Yahoo Finance4h
CRISPR Therapeutics AG (CRSP)
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.